American Well Corp Dossier - Source-backed chat

American Well Corp

AMWLNYSE

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.44

Intrinsic Value $17.21median of 2 methodsbased on filings through 30 Jun 2026

Market Price $13.58Price as of 30 Sep 2026

UndervaluedIntrinsic value is 27% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $231M

Enterprise Value $35M

Shares Outstanding 16.9M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

American Well Corp (Amwell) is undergoing a critical strategic transition from a low-margin, visit-heavy telehealth provider to a high-margin, tech-enabled SaaS hybrid care platform (Converge). While the company has made substantial progress in narrowing its operating losses and reducing cash burn through aggressive cost-cutting, it continues to face top-line headwinds with declining subscription revenues due to historical customer churn. The balance sheet remains robust with $179 million in cash and zero debt, providing sufficient runway to target operating cash flow breakeven by Q4 2026. However, high customer concentration and intense competition warrant a cautious Hold stance until top-line stabilization and sustainable cash generation are demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.50

Mean target$8.90

High · most bullish analyst$16.00

Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

The bear case involves further customer attrition during the Converge migration, failure to renew or expand the DHA contract on favorable terms, or delays in achieving cash flow breakeven. Continued top-line contraction combined with high customer concentration (where two clients represent 58% of revenue) could lead to renewed liquidity concerns and downward pressure on the stock.

Base CaseCentral scenario

$7.5060%

The base case assumes Amwell successfully executes its cost-discipline measures, leading to operating cash flow breakeven in Q4 2026. Revenue remains flat to slightly down in the near term, aligning with the FY 2026 guidance of $195 million to $205 million, as subscription churn is offset by higher-value clinical program visits. Valuation multiples stabilize as the business model shifts permanently toward recurring software revenue.

Bull CaseUpside scenario

$16.0025%

The bull case is predicated on successful global deployment and expansion of the Defense Health Agency (DHA) contract, rapid migration of health plans and health systems to the Converge platform, and successful upsells of high-value clinical programs (such as SilverCloud behavioral health). Under this scenario, top-line growth resumes in late 2026, and operating leverage from the SaaS model drives rapid margin expansion, pushing the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $179 million in cash and cash equivalents and zero debt as of Q1 2026.
Significant operational efficiency gains, with Q1 2026 operating expenses down 31% year-over-year and adjusted EBITDA loss narrowing to $3.1 million.
Strategic shift toward a higher-margin SaaS model, with subscription software revenue representing 53% of total revenue.
Strong growth in high-value clinical programs, with virtual primary care visits up 57% year-over-year in Q1 2026.

Key Investment Risks

High customer concentration, with two clients accounting for 58% of total Q1 2026 revenue.
Persistent top-line pressure, with Q1 2026 revenue declining 18% year-over-year due to customer churn.
Intense competition in the digital care and telehealth infrastructure market from both pure-play peers and EHR vendors.
Execution risks associated with the ongoing migration of legacy clients to the Converge platform.

Thesis Invalidation Triggers

Failure to secure the Defense Health Agency (DHA) base contract renewal by early Q3 2026.
A material delay in the timeline for achieving operating cash flow breakeven beyond Q4 2026.
Loss of either of the two major clients that represent a combined 58% of total revenue.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.